|
|Section2= |Section3= }} Evofosfamide (INN,〔(WHO Drug Information; Recommended INN: List 73 )〕 USAN;〔(Adopted Names of the United States Adopted Names Council )〕 formerly known as TH-302) is an investigational hypoxia-activated prodrug that is in clinical development for cancer treatment. The prodrug is activated only at very low levels of oxygen (hypoxia). Such levels are common in human solid tumors, a phenomenon known as tumor hypoxia. Evofosfamide is being evaluated in clinical trials for the treatment of multiple tumor types as a monotherapy and in combination with chemotherapeutic agents and other targeted cancer drugs. ==Collaboration== Evofosfamide (TH-302) was developed by Threshold Pharmaceuticals Inc. (Threshold).〔(Website of Threshold Pharmaceuticals Inc. )〕 The company is located in South San Francisco, CA, USA. In 2012, Threshold signed a global license and co-development agreement for evofosfamide with Merck KGaA, Darmstadt, Germany (EMD Serono Inc. in the US and Canada), which includes an option for Threshold to co-commercialize eofosfamide in the United States. Threshold is responsible for the development of evofosfamide in the soft tissue sarcoma indication in the United States. In all other cancer indications, Threshold and Merck KGaA are developing evofosfamide together.〔(Threshold Pharmaceuticals and Merck KGaA Announce Global Agreement to Co-Develop and Commercialize Phase 3 Hypoxia-Targeted Drug TH-302 - Press release from 3 February 2012 )〕 From 2012 to 2013, Merck KGaA paid 110 million US$ for upfront payment and milestone payments to Threshold. Additionally, Merck KGaA covers 70% of all evofosfamide development expenses.〔(Threshold Pharmaceuticals Form 8-K from 3 Nov 2014 )〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Evofosfamide」の詳細全文を読む スポンサード リンク
|